1World Health Organization. WHO Collaborating Center for Drug Monitoring. The importance of pharmacovigilance. 2002.
2O'neill RT. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in premarket licensure application safety data, post-market alert reports and formal epidemiological studies, StatistMed, 1998,17: 1851-1858.
3Waller PC,Lee EH. Responding to drug safety issues. Pharmacoepidemiology and Drug Safety, 1999, 8: 535-552.
4Bennett CL, Nebeker JR, Lyons EA, et al. The research on adverse events and reports (RADAR) project, JAMA, 2005, 293: 2131-2140.
5Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. British Journal of Clinical Pharmacology, 2003, 57(2): 127-134.
6Hauben M,Zhou Xiaofeng.Quantitative methods in pharmacovigilance. Drug Safety, 2003, 26(3): 159-186.
7Rothman KJ, Greenland S. Modern Epidemiology(2nd edition). Lippincott: Williams&Wilkins, 1998.
8Shakir SAW, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology. Drug Safety, 2002, 25 (6): 467-471.
9Strom BL. Pharmacoepidemiology (3rd edition). Chichester: Wiley and Sons Ltd, 2000.
